![]() Poor treatment and poorly controlled high blood pressure are responsible for deaths caused by coronary artery disease (50%), stroke (33%), and renal failure (10% to 15%). Furthermore, 16.5% and 9.6% of men and women had elevated blood pressure, respectively. The prevalence of Stage 1 and 2 hypertension was 32.9% and 19.1% for men and 26.3% and 18.0% for women. In Iran, in 2019, the overall prevalence of HTN was reported to be 52.0% and 44.3% in men and women, respectively. In Far-Eastern and Middle-Eastern countries, the prevalence of high blood pressure in various studies is reported to be 10% to 17%. , Of every three over 20-year-old adults in the United States, 1 suffers from hypertension. ,, Hypertension is also the most common risk factor for kidney disease, heart disease, and cerebrovascular disease. ,, , One of the most important factors in the development of cardiovascular disease is hypertension. Available from: Ĭardiovascular disease is the most common cause of death in most countries of the world, including Iran. Effectiveness of smartphone-based medication reminder application on medication adherence of patients with essential hypertension: A clinical trial study. How to cite this URL: Mohammadi Torkabad S, Negahban Bonabi T, Heidari S. How to cite this article: Mohammadi Torkabad S, Negahban Bonabi T, Heidari S. Keywords: Essential hypertension, Medication adherence, Smartphone, Software Three months after the intervention, the ratio of good medication adherence and medication adherence scores was significantly improved in the DaroYab software group (P < 0.001).Ĭonclusions: Considering the positive impact of DaroYab as a simple, practical, and inexpensive drug reminder, on medication adherence it is recommended that health-care providers introduce this application to of hypertensive patients and encourage them to use it. ![]() All of the participants had a history of drug forgetfulness and 92.5% of them had poor medication adherence before the intervention. Results: The mean age of the 78 patients who completed the study was 46.6 ± 7.98 years. Statistical Analysis Used: Data were analyzed using IBM SPSS, American multinational technology company, Armonk, New York and nonparametric tests including the Wilcoxon test and Mann–Whitney U-test. The MMAS-8 completed prior to and 3 months after the intervention. Data were collected using demographic characteristics form and Morriskey's medication adherence scale (MMAS-8). In the intervention group, the DaroYab 2.1.0 was installed on the patient's smartphone. Material and Methods: Seventy-eight patients with essential hypertension were assigned to intervention (39 patients) and control (39 patients) groups using a random sampling method. Settings and Design: This clinical trial study was conducted in Yazd Cardiac Research Center. Source of Support: None, Conflict of Interest: NoneĬontext: Failure to adhere to drug therapy in patients with high blood pressure can endanger their lives.Īims: The aim of this study was to determine the effectiveness of smartphone-based medication reminder application on medication adherence of patients with essential hypertension. Shahin Heidariĭepartment of Fundamental Nursing, Geriatric Care Research Center, School of Nursing and Midwifery, Rafsanjan University of Medical Sciences, Rafsanjan ![]() Sajede Mohammadi Torkabad 1, Tayebeh Negahban Bonabi 2, Shahin Heidari 3ġ Department of Operating Room, Zeyaei Hospital, Shahid Sadoughi University of Medical Sciences, Ardakan, Yazd, Iran 2 Department of Community Health Nursing, Determinants of Health Research Center, School of Nursing and Midwifery, Rafsanjan University of Medical Sciences, Rafsanjan, Iran 3 Department of Fundamental Nursing, Geriatric Care Research Center, School of Nursing and Midwifery, Rafsanjan University of Medical Sciences, Rafsanjan, Iran Date of SubmissionĬorrespondence Address: Dr. Effectiveness of smartphone-based medication reminder application on medication adherence of patients with essential hypertension: A clinical trial study ![]()
0 Comments
Leave a Reply. |